



Published in final edited form as:

J Clin Immunol. 2021 February ; 41(2): 294–302. doi:10.1007/s10875-020-00931-2.

When Screening for Severe Combined Immunodeficiency (SCID) with T Cell Receptor Excision Circles Is Not SCID: a Case-Based Review

David Buchbinder^{1,2}, Jolan E. Walter^{3,4}, Manish J. Butte⁵, Wan-Yin Chan⁶, Maria Chitty Lopez³, Victoria R. Dimitriadis⁷, Morna J. Dorsey⁸, Diane J. Nugent^{1,2}, Jennifer M. Puck⁸, Jasjit Singh⁹, Cathleen A. Collins^{10,11}

¹Department of Hematology, Children's Hospital of Orange County, Orange, CA, USA

²Department of Pediatrics, University of California at Irvine, Orange, CA, USA

³Division of Pediatric, University of South Florida at Johns Hopkins All Children's Hospital, Allergy/ Immunology, St. Petersburg, FL, USA

⁴Division of Pediatric Allergy and Immunology, Massachusetts General Hospital for Children, Boston, MA, USA

⁵Division of Immunology, Allergy, and Rheumatology, Department of Pediatrics, University of California Los Angeles, Los Angeles, CA, USA

⁶Department of Allergy & Immunology, Children's Hospital of Orange County, Orange, CA, USA

⁷Division of Allergy, Immunology & Rheumatology, Department of Pediatrics, Sacramento, CA, USA

⁸Department of Allergy & Immunology, University of California, San Francisco, CA, USA

⁹Department of Infectious Disease, Children's Hospital of Orange County, Orange, CA, USA

¹⁰Department of Pediatrics, Division of Allergy Immunology, University of California at San Diego, La Jolla, CA, USA

¹¹Department of Pediatrics, Division of Allergy Immunology, Rady Children's Hospital, San Diego, CA, USA

Abstract

Newborn screening efforts focusing on the quantification of T cell receptor excision circles (TRECs), as a biomarker for abnormal thymic production of T cells, have allowed for the identification and definitive treatment of severe combined immunodeficiency (SCID) in asymptomatic neonates. With the adoption of TREC quantification in Guthrie cards across the

[✉]David Buchbinder, dbuchbinder@choc.org.

Authors' Contributions All authors helped draft and approved the submitted manuscript. CAC and DB coordinated the creation of the original draft manuscript. DB, MJB, WYC, VRD, MJD, DJN, JMP, JS, and CAC participated in regular teleconferences surrounding the diagnostic evaluation and treatment of the immune disorders depicted in each case. All authors helped review the literature and cases. JEW and MCL helped illustrate the manuscript with the accompanying tables.

Conflict of Interest The authors declare that they have no conflict of interest.

USA and abroad, typical, and atypical SCID constitutes only ~ 10% of cases identified with abnormal TRECs associated with T cell lymphopenia. Several other non-SCID-related conditions may be identified by newborn screening in a term infant. Thus, it is important for physicians to recognize that other factors, such as prematurity, are often associated with low TRECs initially, but often improve with age. This paper focuses on a challenge that immunologists face: the diagnostic evaluation and management of cases in which abnormal TRECs are associated with variants of T cell lymphopenia in the absence of a genetically defined form of typical or atypical SCID. Various syndromes associated with T cell impairment, secondary forms of T cell lymphopenia, and idiopathic T cell lymphopenia are identified using this screening approach. Yet there is no consensus or guidelines to assist in the evaluation and management of these newborns, despite representing 90% of the patients identified, resulting in significant work for the clinical teams until a diagnosis is made. Using a case-based approach, we review pearls relevant to the evaluation of these newborns, as well as the management dilemmas for the families and team related to the resolution of genetic ambiguities.

Keywords

Newborn screening; idiopathic T cell lymphopenia; secondary T cell lymphopenia; syndromes associated with T cell lymphopenia

Introduction

Severe combined immunodeficiency (SCID) is a group of genetically heterogeneous primary immunodeficiency disorders (PIDDs) associated with abnormal T cell differentiation and/or function as well as varying degrees of abnormalities of B and NK cell development [1]. Quantification of T cell receptor excision circles (TRECs) from dried blood spots collected from every newborn in the United States (US) and other countries, is a biomarker for T cell receptor rearrangement and naïve T cells egressing from the thymus [2, 3]. Screening with the quantification of TRECs ensures that most newborns with typical and atypical SCID are diagnosed prior the onset of infections, allowing for rapid triage and institution of definitive therapies [2, 3].

It is of high importance that SCID is distinguished from those patients with athymia where thymic transplantation is preferred as definitive therapy. These two groups can be difficult to distinguish at birth based solely on clinical and immunological presentation. Genetic testing and sophisticated functional assays, such as the use of an in vitro artificial thymic environment, may provide a solution to this conundrum [4, 5]. The evaluation and management of newborns with a range of conditions other than SCID variants and athymia which are increasingly being identified because of these screening efforts, is a growing challenge for immunologists globally.

A recent report from the State of California documented the results of screening 3.2 million newborns using quantification of TRECs [6]. Most of the newborns with T cell lymphopenia were diagnosed with syndromes other than typical or atypical SCID (in decreasing order of frequency: DiGeorge syndrome, trisomy 21, ataxia telangiectasia, CHARGE syndrome, diabetic embryopathy, CLOVES syndrome, EXTL3 deficiency, Fryns syndrome, Nijmegen

syndrome, Noonan syndrome, and RAC2 deficiency). There were 28 newborns with true T cell lymphopenia and no identified disorder.

Despite the expansion and application of next generation sequencing (NGS) techniques including whole exome sequencing (WES) and whole genome sequencing (WGS), there remains a variety of non-SCID disorders that are associated with low TRECs and T cell lymphopenia identified as a result of newborn screening efforts, but without a clear genetic correlate [7, 8]. Similarly, other states, such as New York, reported on patients with idiopathic T cell lymphopenia identified by newborn screening for SCID [9]. One of the syndromes that was most recently associated with borderline abnormal TRECs is WHIM syndrome (warts, hypogammaglobulinemia, infections, and myelokathexis) for which targeted therapy is available. Therefore, for WHIM and other non-SCID lymphopenias, early diagnosis and treatment could improve clinical outcomes [10, 11]. Table 1 summarizes secondary conditions associated with non-SCID T cell lymphopenia that may be identified by newborn screening (NBS) for SCID. Tables 2 and 3 highlight the clinical and laboratory definition of SCID as well as the categorization of immunophenotype by genetic etiologies.

Immunologists may not be familiar with the diagnostic approach or the appropriate therapies available for rare disorders. Opportunities exist for immunologists to work together to develop evidence-based guidelines to assist clinicians in the diagnostic evaluation and management of these newborns [19]. With this goal in mind, we discuss evaluation and management of SCID and non-SCID cases that have been identified from the newborn screening program and pertain to the three following diagnostic categories: (1) syndromes associated with T cell impairment, (2) prematurity and secondary forms of T cell lymphopenia, and (3) idiopathic T cell lymphopenia. Additionally, we will briefly discuss challenges that have arisen in the context of the evaluation and treatment of these newborns, including those associated with the genetic ambiguities that often arise because of in-depth evaluations.

Syndromes Associated with T Cell Impairment

Various syndromes are frequently reported in association with abnormal TRECs and nonSCID T cell lymphopenia [7]. For the more common etiologies, such as 22q11.2 deletion syndrome or Trisomy 21, a careful and complete clinical exam coupled with a basic genetic evaluation including a karyotype and comparative genomic hybridization (CGH) array provides adequate clues to a timely and accurate diagnosis. For the rare etiologies, a delay in diagnosis may occur. Importantly, in some cases, a timely and accurate diagnosis is critical.

Case #1 An 8-day-old female was born at 34 2/7 weeks following a cesarean delivery weighing 2610 g. Maternal history included insulin dependent diabetes. The patient was observed to have facial dysmorphism, vertebral anomalies, bilateral hydronephrosis, and a patent ductus arteriosus and diffuse erythroderma. A positive newborn screen for SCID with a TREC = 0 copy/ μ L (reference range > 18 copies/ μ L) was reported on the newborn screen. Isolation and cessation of breast milk was instituted until the mother was tested for cytomegalovirus (CMV) status. On the complete blood count eosinophilia was present (1170 count/ μ L). The absolute lymphocyte count (ALC) was 2250 count/ μ L comprising CD3+

1417/ μ L, CD4+ 1298/ μ L, CD8+ 120/ μ L, CD4+CD45RA+ 12/ μ L (1% of CD4+ T cells), CD4+CD45RO+ 1223 (99%), CD8+ CD45RA+ 1 (1% of CD8+ T cells), CD8+CD45RO+ 116 (99%). However, the other lymphocyte subsets showed normal numbers (CD19+ 382/ μ L, and NK 264/ μ L). A karyotype was normal (46, XX) and a CGH array did not show 22q11.2. deletion. A primary immunodeficiency NGS panel, WES, and WGS did not identify any rare, or diagnostic pathogenic variants. Transient hypocalcemia and necrotizing enterocolitis occurred. After progression of the rash, increasing white blood cell count (WBC) (55,000/ μ L), adenopathy, and respiratory distress, corticosteroids were started. Immunological studies prior to treatment were notable for an IgG 814 mg/dL, IgM 79 mg/dL, IgA < 8 mg/dL, and IgE 1251 kU/L and diminished lymphocyte proliferation to phytohemagglutinin (PHA).

Prophylaxis included Bactrim, fluconazole, immunoglobulin replacement therapy (0.5 g/kg), and palivizumab to prevent respiratory syncytial virus (RSV) infection. Differential diagnosis still included both SCID and athymia-related conditions. CD34+ cells were isolated from peripheral blood and in vitro differentiation of CD34+ cells to T cells was normal supporting the diagnosis of primary athymia. Thymic transplantation was recommended.

The findings of remarkably normal appearing T cell counts in peripheral blood can be misleading, as these self-reactive T cells mainly have an activated phenotype (CD45RO), do not express naïve markers (CD45RA), and display an oligoclonal TCR V β repertoire. In this case, the clinical features of eosinophilia and a diffuse erythematous rash coupled with a predominance of memory T cells (99% of CD4+ and CD8+ T cells express CD45RO) suggested the possibility of Omenn syndrome (OS). OS-like features result from T cell infiltration of the skin causing erythroderma, as well as T cell infiltration, activation and expansion in the lymph nodes, gut, liver, and lung [20]. Although recombinase activating gene (*RAG1* and *RAG2*) hypomorphic variants were the first reported cause of OS; there are several other SCID gene variants linked to OS that result in defects involving metabolic pathways (*AK2*, *RMRP*, *ADA*), T cell signaling (*IL7RA*, *IL2RG*, *ZAP70*), V(D)J recombination [*DCLRE1C* (Artemis)], *LIG4* activity (DNA ligase IV), and thymic formation and function (partial DiGeorge syndrome with 22q11.2 deletion or *TBX1* mutation) and even CHARGE syndrome, with coloboma, heart defects, atresia choanae, growth retardation, genital abnormalities, and ear abnormalities [21–28]. In addition to OS, maternal lymphocyte engraftment with SCID or athymia was also considered [29]. DNA typing with variable number of tandem repeat (VNTR) loci was completed as a sensitive method to exclude maternal engraftment.

Athymia can be seen in CHARGE syndrome as well as within a variety of genetic disorders including 22q11.2 deletion syndrome (22qDS), *PAX1* deficiency, or biallelic mutations in *FOXN1* [30–32]. Dominant negative (heterozygous) mutations in *FOXN1* have also been associated with diminished thymic function in patients with and without nail dystrophy and alopecia [33]. Moreover, complete athymia in patients with *FOXN1* deficiency may occur without concurrent hair and nail abnormalities [34]. In 22qDS, patients frequently present with congenital heart disease and hypoparathyroidism, but those findings are sometimes absent [35]. Patients with athymia typically have low or absent T cells as well as diminished

proliferative response to phytohemagglutinin [35]. In case #1, in addition to low numbers of overall T cells, proliferation to PHA was diminished. Because athymic patients can develop autoreactivity within their limited T cell compartment, immunosuppression using corticosteroids and calcineurin inhibitors, as well as other anti-T cell therapies, is often required as a bridge to thymic transplantation, which is curative [35, 36]. In a case like this, the timely decision to proceed with hematopoietic stem cell transplantation (HSCT) versus thymic transplantation is critical, so diagnostic efforts should not be delayed. Importantly, patients with athymia do not require HSCT, although in selected cases HSCT resulted in partial immune reconstitution but not cure [37].

The absence of naïve T cells is an important feature which is common to both SCID and athymia, and these can be identified by looking for presence of recent thymic emigrants that can be defined by CD45RA+CD31+ expression among CD4+ T cells. As we did not have a candidate gene on WES and WGS, we distinguished the possibility of athymia from SCID with a novel platform. Utilizing 5–10 mL of peripheral blood or bone marrow, research labs have developed methods to measure in vitro differentiation and positive selection of conventional human T cells from CD34+ cells using a variety of techniques including the use of an artificial thymic organoid system [4, 5]. Patients with isolated athymia as their only problem, can develop T cells in this assay, whereas those patients with other intrinsic defects of lymphocyte development do not.

As we described above, breastfeeding was discontinued in our patient to avoid exposure and infection with CMV from the mother. One important aspect of the management of syndromes associated with T cell impairment includes the issue of whether to withhold breastfeeding due to risk of transmission of maternal CMV [38, 39]. It is vital to consider the CD3+ T cell count and the percentage of naïve T cells present; however, the risks of transmission of CMV through breast milk in infants with T cell lymphopenia has not been studied in a large cohort allowing clinicians to safely identify a protective level of T cells [38]. Checking maternal CMV titers is vital to establish the risk of transmission prior to clearing further breast milk exposure and breastfeeding. Even in cases where mothers are seronegative for CMV, there have been cases of CMV transmission during maternal primary infection while breastfeeding.

Another important aspect of the management of syndromes associated with T cell impairment includes the question of whether to withhold live viral vaccines early in life. For newborns with CD3+ T cell counts < 1500/μL, vaccination with rotavirus is withheld due to concern for adverse events related to vaccination, such as vaccine-derived infections and associated diarrhea. There have been cases of PIDDs, including SCID, which were diagnosed after rotavirus vaccination caused severe gastroenteritis [40, 41]. The recommended schedule of childhood vaccines, except for live-viral vaccines, are typically provided safely to most newborns with syndromes associated with T cell impairment although they may be ineffective depending on the presence of residual immune function. PPSV23 (> 2 years of age) and meningococcal vaccines may also be considered. It is prudent to assure that vaccine responses to killed vaccines are carefully assessed by measuring titers 4–6 weeks following completion of the series.

Although our case was diagnosed with athymia that required immediate thymic transplant, many patients with partial thymic defects may continue without intervention. In these children, if there is an adequate T lymphocyte count and normal antigen response, vaccination with live viral vaccines including Varicella and MMR (not MMRV) may be considered. Adverse events associated with Varicella and MMR are uncommon in defined syndromes associated with T cell impairment or secondary T cell lymphopenia [42, 43]. The difference in recommendations between the Red Book and the Center for Disease Control (CDC) highlight the lack of uniformity in recommendations. Most studies in partial 22qDS document that vaccination with Varicella and MMR are safe with lower numbers of CD4+ T cells when accompanied by normal lymphocyte proliferation to mitogens [44]. MMR is safely administered in infants with CD4+ T cells > 500 cells/mm³. Similarly, other live vaccines including Bacille Calmette-Guerin (BCG) and polio virus have been associated with severe adverse events in the setting of PIDDs [45].

Prematurity and Secondary T Cell Lymphopenia

Prematurity and secondary T cell lymphopenia is frequently encountered in association with abnormal TRECs and non-SCID T cell lymphopenia. T cell lymphopenia is commonly documented among premature and low birth weight newborns [8, 46]. T cell lymphopenia in premature infants is part of the physiologic variation in thymus development. Frequently encountered clinical scenarios associated with secondary T cell lymphopenia include T cell loss which may occur because of lymphatic or gastrointestinal abnormalities [8, 47]. Rarely, other causes of secondary T cell lymphopenia, such as in utero exposures to maternal immunosuppressive agents, have also been described [8, 48].

Case #2 A 26-day-old male was born at 23 weeks weighing 540 g. He experienced multiple complications of extreme prematurity. A positive newborn screen for SCID with TREC = 10 (reference range > 18/ μ L) was documented. A complete blood cell count demonstrated an ALC of 2680/ μ L (ref range 2500–16,500). Flow cytometry demonstrated normal proportions of T, B and NK cells; however, the absolute number of T cells was documented at 1460/ μ L. Recent data provide lymphocyte subset reference ranges for premature infants. For this neonate, projected to be 27 weeks estimated gestational age, the median (5–95% CI) for absolute T cell counts is 1798/ μ L (900–3608). Furthermore, 78% of the CD4+ T cells and 74% of the CD8+ T cells expressed CD45RA, a marker identifying naive T cells, suggestive of adequate thymic function and production of T cells. These data were consistent with a diagnosis of T cell lymphopenia in association with prematurity, and no further immunological testing was advised. Standard care for age, clinical status, and degree of maturity of the newborn was recommended including routine childhood vaccination as well as live viral vaccination (e.g., rotavirus) when appropriate.

This case demonstrates that, in the setting of prematurity, it is vital to use recently published reference ranges to correctly interpret lymphocyte immunophenotyping data among otherwise healthy preterm or low birthweight newborns [46]. Absolute numbers of T cells and B cells increase postnatally among preterm and low birthweight newborns; however, absolute numbers of NK cells appear to remain constant postnatally. Close follow-up of these preterm newborns may not be necessary; however, repeat lymphocyte

immunophenotyping and additional assessments of immune system function may be performed as dictated by the clinical scenario.

Secondary lymphopenia may develop with other conditions, as listed in Table 1. Neonatal complete thymectomy is associated with later reduction in T cell counts due to decreased production [49]. Moreover, the treatment of congenital heart disease resulting in thymectomy, thoracic duct pathology, and protein losing enteropathy may also be associated with lymphocyte loss [50, 51]. Underlying syndromes may also be associated with congenital heart disease alone or in combination with abnormal lymphatic development such as intestinal lymphangiectasia and chylothorax leading to lymphocyte loss [47]. Gastroschisis and intestinal atresia may also be associated with abnormal lymphatic development and lymphocyte loss. A careful and complete clinical examination often coupled with specific genetic evaluations can provide clues to the diagnosis. Moreover, in addition to the loss of lymphocytes, proteins may also be lost resulting in hypoalbuminemia and hypogammaglobulinemia, a clue that can often be overlooked. Close follow-up of these newborns may be necessary with repeat lymphocyte immunophenotyping once the underlying cause of lymphocyte loss is corrected.

Case #3 A 6-week-old infant was born at 39 weeks gestation weighing 3830 g. She had a prenatal diagnosis of gastroschisis and required intubation shortly after birth due to apnea. A positive newborn screen for SCID with TREC = 15 (reference range > 18/ μ L) was documented. The CBC showed an absolute lymphocyte count of 2290 cells/ μ L. The lymphocyte subsets were low with 1266 CD3+ T cells/ μ L (normal > 1512), 988 CD4+ T cells/ μ L (nl > 1025), and 208 CD8+ T cells/ μ L (nl > 400) (reference ranges per Amatuni et al. [6]). Naive, newly formed T cells (CD45RA+) comprised 61% and 61% of the CD4+ and CD8+ subsets, respectively, giving an indication of some new T cell generation in the thymus. B cell number was normal at 640 cells/ μ L, as was NK cell number at 202 cells/ μ L. Overall, these results were not considered normal but were sufficient to rule out typical SCID and were consistent with her diagnosis of gastroschisis. At that time, it was recommended that infectious precautions be implemented and that live vaccines be held; the remainder of vaccinations was carried out per normal scheduling. Repeat lymphocyte enumeration completed 2 months after her gastroschisis repair revealed normalization of the T cell compartment with normal mitogen proliferation.

In utero exposure to maternal immunosuppressive agents has also been documented as an important etiology of secondary T cell lymphopenia among newborns [48]. This underscores the need for a careful and complete clinical history of all newborns with non-SCID T cell lymphopenia. There have been cases with T cell lymphopenia due to in utero exposures to purine antagonists such as azathioprine and 6-mercaptopurine, as well as in utero exposures to anti-TNF alpha agents such as adalimumab. In these cases, the T cell lymphopenia typically resolved over time. However, these newborns may require consideration of supportive care measures such isolation, cessation of breast milk feeding, and prophylactic antibiotics including trimethoprim/sulfamethoxazole as well as avoidance of live viral vaccines due to the extremely low numbers of T cells.

Idiopathic T Cell Lymphopenia

Idiopathic T cell lymphopenia is encountered; however, its course remains variable [9]. Previous studies document that some newborns will have improvement fairly quickly whereas a subset of these newborns will not have appreciable improvement in T cell counts at all postnatally. A careful and complete clinical exam as well as a detailed laboratory assays, including the application of NGS typically fails to provide adequate clues to an underlying diagnosis in these cases. Careful clinical and laboratory reassessment is often necessary as a specific diagnosis may become apparent over time.

Case #4 A 7-day-old female was born at 39 weeks following a cesarean delivery weighing 3700 g. Maternal history was unremarkable. A preauricular skin tag with a normal hearing screen was documented. A positive NBS for SCID with a TREC = 5 (reference range > 18/ μ L) was documented. Isolation and cessation of breast milk was instituted. The ALC was 530/ μ L with CD3+ 172/ μ L, CD4+ 153/ μ L, CD8+ 3/ μ L, with preserved naïve T cell compartment (CD3+CD4+ CD45RA+ 125/ μ L (82%), CD3+CD8+CD45RA+ < 20/ μ L (71%)) and normal B lymphocyte and NK cell counts (CD19+79/ μ L, NK 243/ μ L). Mitogen proliferation to PHA was normal. Immunoglobulin levels demonstrated an IgG 817 mg/dL, IgM 13 mg/dL, and IgA < 8 mg/dL. Maternal engraftment was excluded using analysis of VNTR loci. A CGH array was negative for 22q11.2 deletion. A primary immunodeficiency NGS panel, WES, and WGS were all non-diagnostic. Prophylaxis included Bactrim, fluconazole, immunoglobulin, and palivizumab. At 41 days of age, a repeat ALC was 3770/ μ L with normalized T cell subsets (CD3+ 2357/ μ L, CD4+ 1863/ μ L, CD8+ 475/ μ L), CD19+519/ μ L, NK 791/ μ L, CD3+CD4+CD45RA+ 1496/ μ L (80%), CD3+ CD8+CD45RA+ 418/ μ L (88%). Supportive care was stopped, and the infant was discharged to home with outpatient follow-up.

Idiopathic T cell lymphopenia remains a diagnosis of exclusion. Care must be taken to carefully exclude previously aforementioned causes of T cell lymphopenia including syndromes associated with T cell impairment and secondary causes of T cell lymphopenia. In contrast to premature newborns whose T cell lymphopenia tends to improve postnatally, full-term newborns with idiopathic T cell lymphopenia may have persistently low T cell counts that do not improve over time. Follow-up of 26 newborns with idiopathic T cell lymphopenia documented that counts increased in 17 and decreased in 9, over a period of 6 to 66 months of follow-up. Another study of 33 newborns with idiopathic T cell lymphopenia documented that 13 resolved or improved, 13 were persistent and 6 became lost to follow-up [6, 9].

Ongoing evaluation of idiopathic T cell lymphopenia beyond the newborn period could include specific laboratory assessments such as a serum alpha fetoprotein at 6 months of age to help direct further evaluations for ataxia telangiectasia prior to the development of the classic features of progressive cerebellar ataxia and oculocutaneous telangiectasias [52]. In-depth genetic assessments using NGS techniques such as WES and WGS may be considered depending on the clinical scenario. Long-term follow-up and periodic reanalysis of sequencing data are recommended if lymphopenia persists. Recommendations regarding the extent of evaluation for individual patients and the duration of follow-up that is necessary

are unknown. Moreover, in this population, specific guidelines surrounding the safety of breastfeeding and vaccination with live viral vaccines including rotavirus vaccine remains uninvestigated and thus undefined. In addition, the safety and long-term impact of genetic testing in young infants is also unclear; genetic counseling should be a part of the evaluation if this is pursued.

Challenges: Screening, Genetics, and Ambiguities

The quantification of TRECs is a screening test that can detect most cases of typical and atypical SCID with only rare exceptions. Despite this, challenges arise when considering the evaluation of the non-SCID newborns with T cell lymphopenia identified by these screening efforts. Despite early identification, some families may refuse further workup for a variety of reasons including inconvenience, lack of understanding of the urgency for diagnosis and treatment, as well as denying the severity of the disorder. In addition, when we do continue investigations, they often create additional work for case managers and MDs trying to get authorizations or dealing with insurance denials, only to be challenged by the ambiguity of genetic sequencing data resulting in lengthy and laborious diagnostic evaluations carried out by multiple research labs. This scenario may lead to parental frustration and refusal of additional diagnostic evaluation.

Case #5 An 8-day-old male was born at 37 weeks of gestation following an uncomplicated pregnancy and vaginal delivery. Aside from hyperbilirubinemia and weight loss, facial dysmorphism as well as anomalies of the hands and toes suggested possible Trisomy 21. A positive NBS for SCID with a TREC = 1/μL (reference range > 18) was documented. Isolation and cessation of breast milk was instituted. The ALC was 550 /μL with CD3+154/μL, CD4+ 94/μL, CD8+ 56/μL, CD19+ < 20/μL, CD16/56+ NK cells < 20/μL, CD3+CD4+CD45RA+ 63/μL (67%), CD3+CD8+CD45RA+ 54/μL (96%). Mitogen proliferation to PHA was normal. Maternal engraftment was excluded using analysis of VNTR loci. A CGH array was negative for 22q11.2 deletion but did demonstrate changes consistent with a translocation form of Down syndrome. A primary immunodeficiency NGS panel also demonstrated one pathogenic variant in RAG1 and one variant of uncertain significance (VUS) in RAG1. Prophylaxis included Bactrim, fluconazole, immunoglobulin, and palivizumab. Additional testing to evaluate the pathogenicity of the heterozygous VUS in RAG1 was recommended. The family refused supportive care and additional laboratory evaluation as well as outpatient follow-up.

The increasing application of NGS has also led to challenges in the resolution of ambiguous results. Despite the application of bioinformatics, the ability to query databases, and the use of prediction tools focusing on a VUS, ambiguity still exists. Characterizing the segregation of the variant within the family as well as standardized reanalysis can be useful when evaluating a VUS. Collaboration with research laboratories or other professional groups of clinicians and scientists may support the ability to glean additional functional information about the VUS. For example, in the case above, flow cytometry can be used to detect utilization of the Va7.2 TCR gene segment in CD3+ T lymphocytes and/or mucosa-associated invariant T-169 cells (MAIT). This serves as a rapid method for evaluating

decreased usage of distal TCRAV (TRAV) gene segments, which suggests the presence of a underlying V(D)J recombination defect such as RAG deficiency [53].

Ultimately, however, the clinical phenotype coupled with laboratory assessments of immunologic function contribute to the decision to embark on curative therapies such as HSCT since intervention may need to occur before the results of additional testing (e.g., reanalysis) can provide more insight. In some cases, though, the exact genetic variant causing disease can be of high importance, especially in the era of personalized gene therapy. A recent publication categorized a novel variant initially classified as a VUS in two X-SCID patients identified by newborn screening. Functional assays and maternal X-inactivation studies were needed to confirm the pathogenicity of the novel variants [54]. In cases such as this, identification of the exact mutation is vital and can aid in planning for future therapies. Somatic mosaicism and somatic reversion are two other potential etiologies of T cell lymphopenia that might elude causal genetic analysis [55].

Conclusions

Immunologists continue to face challenges associated with the diagnosis and management of newborns with a range of conditions other than SCID which are increasingly identified because of these screening efforts. Familiarity with these common scenarios is vital to ensure that a thorough evaluation and appropriate management are provided. Creating a multiinstitutional collaborative to assist in the definition of best practices with respect to the diagnostic evaluation and management provided for these newborns will streamline the workup and diagnosis ensuring optimal treatment and even lifesaving therapies for individual patients.

References

1. Chinn IK, Shearer WT. Severe combined immunodeficiency disorders. *Immunol Allergy Clin N Am.* 2015;35(4):671–94.
2. Puck JM. Newborn screening for severe combined immunodeficiency and T-cell lymphopenia. *Immunol Rev.* 2019;287(1):241–52. [PubMed: 30565242]
3. van der Burg M, Mahlaoui N, Gaspar HB, Pai SY. Universal newborn screening for severe combined immunodeficiency (SCID). *Front Pediatr.* 2019;7:373. [PubMed: 31620409]
4. Bifsha P, Leiding JW, Pai SY, Colamartino ABL, Hartog N, Church JA, et al. Diagnostic assay to assist clinical decisions for unclassified severe combined immune deficiency. *Blood Adv.* 2020;4(12):2606–10. [PubMed: 32556280]
5. Bosticardo M, Pala F, Calzoni E, Delmonte OM, Dobbs K, Gardner CL, et al. Artificial thymic organoids represent a reliable tool to study T-cell differentiation in patients with severe T-cell lymphopenia. *Blood Adv.* 2020;4(12):2611–6. [PubMed: 32556283]
6. Amatuni GS, Currier RJ, Church JA, Bishop T, Grimbacher E, Nguyen AA, et al. Newborn screening for severe combined immunodeficiency and T-cell lymphopenia in California, 2010–2017. *Pediatrics.* 2019;143(2):e20182300. [PubMed: 30683812]
7. Yska HAF, Elsink K, Kuijpers TW, Frederix GWJ, van Gijn ME, van Montfrans JM. Diagnostic yield of next generation sequencing in genetically undiagnosed patients with primary immunodeficiencies: a systematic review. *J Clin Immunol.* 2019;39(6):577–91. [PubMed: 31250335]
8. Mauracher AA, Pagliarulo F, Faes L, Vavassori S, Güngör T, Bachmann LM, et al. Causes of low neonatal T-cell receptor excision circles: a systematic review. *J Allergy Clin Immunol Pract.* 2017;5(5):1457–1460.e22. [PubMed: 28359806]

9. Albin-Leeds S, Ochoa J, Mehta H, Vogel BH, Caggana M, Bonagura V, et al. Idiopathic T cell lymphopenia identified in New York state newborn screening. *Clin Immunol*. 2017;183:36–40. [PubMed: 28694137]
10. Evans MO 2nd, McDermott DH, Murphy PM, Petersen MM. Abnormal newborn screen in a WHIM syndrome infant. *J Clin Immunol*. 2019;39(8):839–41. 10.1007/s10875-019-00686-5. [PubMed: 31493092]
11. Heusinkveld LE, Yim E, Yang A, Azani AB, Liu Q, Gao JL, et al. Pathogenesis, diagnosis and therapeutic strategies in WHIM syndrome immunodeficiency. *Expert Opin Orphan Drugs*. 2017;5(10): 813–25. [PubMed: 29057173]
12. Dorsey M, Puck J. Newborn screening for severe combined immunodeficiency in the US: Current status and approach to management. *Int J Neonatal Screen*. 2017;3:15. 10.3390/ijns3020015. [PubMed: 31304419]
13. Kobrynski LJ. Identification of severe combined immune deficiency T cell lymphopenia at newborn screening for severe combined immune deficiency. *Ann Allergy Asthma Immunol*. 2019;123: 424–7. 10.1016/j.anai.2019.08.006. [PubMed: 31419489]
14. Shearer WT, et al. Establishing diagnostic criteria for severe combined immunodeficiency disease (SCID), leaky SCID, and Omenn syndrome: the Primary Immune Deficiency Treatment Consortium experience. *J Allergy Clin Immunol*. 2014;133:1092–8. 10.1016/j.jaci.2013.09.044. [PubMed: 24290292]
15. Dorsey MJ, Dvorak CC, Cowan MJ, Puck JM. Treatment of infants identified as having severe combined immunodeficiency by means of newborn screening. *J Allergy Clin Immunol*. 2017;139:733–42. 10.1016/j.jaci.2017.01.005. [PubMed: 28270365]
16. Fernandez IZ, Baxter RM, Garcia-Perez JE, Vendrame E, Ranganath T, Kong DS, et al. A novel human IL2RB mutation results in T and NK cell-driven immune dysregulation. *J Exp Med*. 2019;216:1255–67. 10.1084/jem.20182015. [PubMed: 31040184]
17. Picard C, Bobby Gaspar H, al-Herz W, Bousfiha A, Casanova JL, Chatila T, et al. International Union of Immunological Societies: 2017 primary immunodeficiency diseases committee report on inborn errors of immunity. *J Clin Immunol*. 2018;38:96–128. 10.1007/s10875-017-0464-9. [PubMed: 29226302]
18. Tangye SG, Al-Herz W, Bousfiha A, Chatila T, Cunningham-Rundles C, Etzioni A, Franco JL, Holland SM, Klein C, Morio T, Ochs HD, Oksenhendler E, Picard C, Puck J, Torgerson TR, Casanova JL, Sullivan KE. Human inborn errors of immunity: 2019 update on the classification from the International Union of Immunological Societies Expert Committee. *J Clin Immunol*. 2020 1;40(1):24–64. [PubMed: 31953710]
19. Dorsey MJ, Wright NAM, Chaimowitz NS, Dávila Saldaña BJ, Miller H, Keller MD, Thakar MS, Shah AJ, Abu-Arja R, Andolina J, Aquino V, Barnum JL, Bednarski JJ, Bhatia M, Bonilla FA, Butte MJ, Bunin NJ, Chandra S, Chaudhury S, Chen K, Chong H, Cuvelier GDE, Dalal J, DeFelice ML, DeSantes KB, Forbes LR, Gillio A, Goldman F, Joshi AY, Kapoor N, Knutsen AP, Kobrynski L, Lieberman JA, Leiding JW, Oshrine B, Patel KP, Prockop S, Quigg TC, Quinones R, Schultz KR, Seroogy C, Shyr D, Siegel S, Smith AR, Torgerson TR, Vander Lugt MT, Yu LC, Cowan MJ, Buckley RH, Dvorak CC, Griffith LM, Haddad E, Kohn DB, Logan B, Notarangelo LD, Pai SY, Puck J, Pulsipher MA, Heimall J. Infections in infants with SCID: Isolation, infection screening, and Prophylaxis in PIDTC Centers. *J Clin Immunol*. 2020.
20. Selim MA, Markert ML, Burchette JL, Herman CM, Turner JW. The cutaneous manifestations of atypical complete DiGeorge syndrome: a histopathologic and immunohistochemical study. *J Cutan Pathol*. 2008;35(4):380–5. [PubMed: 18333898]
21. Villa A, Santagata S, Bozzi F, Giliani S, Frattini A, Imberti L, et al. Partial V(D)J recombination activity leads to Omenn syndrome. *Cell*. 1998;93:885–96. [PubMed: 9630231]
22. Wada T, Yasui M, Toma T, Nakayama Y, Nishida M, Shimizu M, et al. Detection of T lymphocytes with a second-site mutation in skin lesions of atypical X-linked severe combined immunodeficiency mimicking Omenn syndrome. *Blood*. 2008;112(5):1872–5. [PubMed: 18559672]
23. Roifman CM, Zhang J, Atkinson A, Grunebaum E, Mandel K. Adenosine deaminase deficiency can present with features of Omenn syndrome. *J Allergy Clin Immunol*. 2008;121(4):1056–8. [PubMed: 18243287]

24. Turul T, Tezcan I, Artac H, de Bruin-Versteeg S, Barendregt BH, Reisli I, et al. Clinical heterogeneity can hamper the diagnosis of patients with ZAP70 deficiency. *Eur J Pediatr*. 2009;168(1):87–93. [PubMed: 18509675]
25. Ege M, Ma Y, Manfras B, Kalwak K, Lu H, Lieber MR, et al. Omenn syndrome due to ARTEMIS mutations. *Blood*. 2005;105(11):4179–86. [PubMed: 15731174]
26. Grunebaum E, Bates A, Roifman CM. Omenn syndrome is associated with mutations in DNA ligase IV. *J Allergy Clin Immunol*. 2008;122(6):1219–20. [PubMed: 18845326]
27. Gennery AR, Slatter MA, Rice J, Hoefsloot LH, Barge D, McLean-Tooke A, et al. Mutations in CHD7 in patients with CHARGE syndrome cause T-B + natural killer cell + severe combined immune deficiency and may cause Omenn-like syndrome. *Clin Exp Immunol*. 2008;153(1):75–80. [PubMed: 18505430]
28. Giliani S, Bonfim C, de Saint Basile G, Lanzi G, Brousse N, Koliski A, et al. Omenn syndrome in an infant with IL7RA gene mutation. *J Pediatr*. 2006;148(2):272–4. [PubMed: 16492442]
29. Muller SM, Ege M, Pottharst A, Schulz AS, Schwarz K, Friedrich W. Transplacentally acquired maternal T lymphocytes in severe combined immunodeficiency: a study of 121 patients. *Blood*. 2001;98(6):1847–51. [PubMed: 11535520]
30. Mehr S, Hsu P, Campbell D. Immunodeficiency in CHARGE syndrome. *Am J Med Genet C: Semin Med Genet*. 2017;175(4):516–23. [PubMed: 29159871]
31. Yamazaki Y, Urrutia R, Franco LM, Giliani S, Zhang K, Alazami AM, et al. PAX1 is essential for development and function of the human thymus. *Sci Immunol*. 2020;5(44):eaax1036. [PubMed: 32111619]
32. Gallo V, Cirillo E, Giardino G, Pignata C. FOXP1 deficiency: from the discovery to novel therapeutic approaches. *J Clin Immunol*. 2017;37(8):751–8. [PubMed: 28932937]
33. Bosticardo M, Yamazaki Y, Cowan J, Giardino G, Corsino C, Scalia G, et al. Heterozygous FOXP1 variants cause low TRECs and severe T cell lymphopenia, revealing a crucial role of FOXP1 in supporting early thymopoiesis. *Am J Hum Genet*. 2019;105(3): 549–61. [PubMed: 31447097]
34. Du Q, Huynh LK, Coskun F, Molina E, King MA, Raj P, et al. FOXP1 compound heterozygous mutations cause selective thymic hypoplasia in humans. *Clin Invest*. 2019;129(11):4724–38.
35. Davies EG. Immunodeficiency in DiGeorge syndrome and options for treating cases with complete athymia. *Front Immunol*. 2013;4: 322. [PubMed: 24198816]
36. Caglayan Sozmen S, Isik S, Arikan Ayyildiz Z, Yildiz K, Cakir Y, Ozer E, et al. Cyclosporin treatment improves skin findings in Omenn syndrome. *Pediatr Dermatol*. 2015;32(2):e54–7. [PubMed: 25727345]
37. Land MH, Garcia-Lloret MI, Borzy MS, Rao PN, Aziz N, McGhee SA, et al. Long-term results of bone marrow transplantation in complete DiGeorge syndrome. *J Allergy Clin Immunol*. 2007;120(4):908–15. [PubMed: 17931564]
38. Kelty WJ, Beatty SA, Wu S, Hanson IC, Demmler-Harrison GJ, Martinez CA, et al. The role of breast-feeding in cytomegalovirus transmission and hematopoietic stem cell transplant outcomes in infants with severe combined immunodeficiency. *J Allergy Clin Immunol Pract*. 2019;7(8):2863–2865.e3. [PubMed: 31326381]
39. Walter JE, Heimall J. CMV-Seropositive Mothers of SCID: To Breastfeed or Not? *J Allergy Clin Immunol Pract*. 2019;7(8): 2866–7. [PubMed: 31706499]
40. Rosenfeld L, Mas Marques A, Niendorf S, Hofmann J, Gratopp A, Kühl JS, et al. Life-threatening systemic rotavirus infection after vaccination in severe combined immunodeficiency (SCID). *Pediatr Allergy Immunol*. 2017;28(8):841–3. [PubMed: 28815852]
41. Bakare N, Menschik D, Tiernan R, Hua W, Martin D. Severe combined immunodeficiency (SCID) and rotavirus vaccination: reports to the Vaccine Adverse Events Reporting System (VAERS). *Vaccine*. 2010;28(40):6609–12. [PubMed: 20674876]
42. Waters V, Peterson KS, LaRussa P. Live viral vaccines in a DiGeorge syndrome patient. *Arch Dis Child*. 2007;92(6):519–20. [PubMed: 16798784]
43. Hofstetter AM, Jakob K, Klein NP, Dekker CL, Edwards KM, Halsey NA, et al. Live vaccine use and safety in DiGeorge syndrome. *Pediatrics*. 2014;133(4):e946–54. [PubMed: 24685951]

44. Al-Sukaiti NR, Lavi B, Al-Zaharani S, Atkinson D, Roifman Chaim M, Grunebaum E. Safety and efficacy of measles, mumps, and rubella vaccine in patients with DiGeorge syndrome. *J Allergy Clin Immunol.* 2010;126(4):868–9. [PubMed: 20810153]
45. El-Sayed ZA, Radwan N. Newborn screening for primary immunodeficiencies: the gaps, challenges, and outlook for developing countries. *Front Immunol.* 2020;10:2987. [PubMed: 32082296]
46. Amatuni GS, Sciortino S, Currier RJ, Naides SJ, Church JA, Puck JM. Reference intervals for lymphocyte subsets in preterm and term neonates without immune defects. *J Allergy Clin Immunol.* 2019;144(6):1674–83. [PubMed: 31220471]
47. Joyce S, Gordon K, Brice G, Ostergaard P, Nagaraja R, Short J, et al. The lymphatic phenotype in Noonan and cardiofaciocutaneous syndrome. *Eur J Hum Genet.* 2016;24(5): 690–6. [PubMed: 26242988]
48. Kuo CY, Garcia-Lloret MI, Slev P, Bohnsack JF, Chen K. Profound T cell Lymphopenia associated with prenatal exposure to purine antagonists detected by TREC newborn screening. *J Allergy Clin Immunol Pract.* 2017;5(1):198–200. [PubMed: 28065337]
49. Mancebo E, Clemente J, Sanchez J, Ruiz-Contreras J, De Pablos P, Cortezon S, et al. Longitudinal analysis of immune function in the first 3 years of life in thymectomized neonates during cardiac surgery. *Clin Exp Immunol.* 2008;154(3):375–83. [PubMed: 18811694]
50. Mattes M, Connor J, Kelly SS, Schwartz MC. Lymphopenia in patients with single-ventricle heart disease after the Fontan operation. *Congenit Heart Dis.* 2016;11(3):270–5. [PubMed: 26554755]
51. Hoskote AU, Ramaiah RN, Cale CM, Hartley JC, Brown KL. Role of immunoglobulin supplementation for secondary immunodeficiency associated with chylothorax after pediatric cardiothoracic surgery. *Pediatr Crit Care Med.* 2012;13(5):535–41. [PubMed: 22760424]
52. Devaney R, Pasalodos S, Suri M, Bush A, Bhatt JM. Ataxia telangiectasia: presentation and diagnostic delay. *Arch Dis Child.* 2017;102(4):328–30. [PubMed: 27799156]
53. Berland A, Rosain J, Kaltenbach S, Allain V, Mahlaoui N, Melki I, et al. PROMIDISalpha: a T-cell receptor alpha 407 signature associated with immunodeficiencies caused by V(D)J recombination defects. *J Allergy Clin Immunol.* 2019;143(1):325–34 e322. [PubMed: 29906526]
54. Purswani P, Meehan CA, Kuehn HS, Chang Y, Dasso JF, Meyer AK, et al. Two unique cases of X-linked SCID: a diagnostic challenge in the era of newborn screening. *Front Pediatr.* 2019;7:55. [PubMed: 31024866]
55. Mensa-Vilaró A, Bravo García-Morato M, de la Calle-Martin O, Franco-Jarava C, Martínez-Saavedra MT, González-Granado LI, et al. Unexpected relevant role of gene mosaicism in patients with primary immunodeficiency diseases. *J Allergy Clin Immunol.* 2019;143(1):359–68. [PubMed: 30273710]

Secondary conditions associated with non-SCID T cell lymphopenia that may be identified by NBS for SCID

Table 1

Syndromes with T cell impairment

CHARGE syndrome (coloboma, heart defects, atresia choanae, growth retardation, genital abnormalities, and ear abnormalities)

Partial DiGeorge syndrome (congenital heart defects, hypoparathyroidism, and hypofunction of thymus)

VACTERL (vertebral defects, anal atresia, cardiac defects, tracheoesophageal fistulas, renal and limb abnormalities)

Trisomy 21 (Down syndrome)

Ataxia-telangiectasia

Trisomy 18 (congenital heart defects and multiple anomalies)

Jacobsen syndrome (developmental delay, dysmorphic facies, abnormal bleeding, attention-deficit/hyperactivity disorder, and frequent ear and sinus infections)

CLOVES (congenital lipomatous [fatty] overgrowth, vascular malformations, and epidermal nevi and scoliosis)

Nijmegen breakage (microcephaly, hypogammaglobulinemia, decrease T cells, increased cancer risk, and abnormal DNA breakage repair)

Fryns (associated with congenital diaphragmatic hernia and dysmorphic features)

Ectrodactyly ectodermic dysplasia syndrome

EXTL3 deficiency (skeletal dysplasia, developmental delay)

Rac2 defect (neutrophil killing defects)

Noonan (dysmorphic facies, short neck, short stature, and congenital heart defects)

Renpenning (*PQBPI* loss of function leading to short stature, intellectual disability and dysmorphism)

Barth syndrome (*TAZ* loss of function leading to cardiomyopathy at birth and neutropenia; mostly affects males)

TAR syndrome (*RBM8A* deficiency leading to thrombocytopenia and absent radius)

WHIM syndrome (*CXCR4* gain of function leading to warts, hypogammaglobulinemia, infections, myelokathexis)

Diabetic embryopathy

Other cytogenetic abnormalities (including metabolic diseases)

T cell loss or destruction

Congenital cardiac anomalies

Gastrointestinal anomalies (gastroschisis, omphalocele and intestinal lymphangiectasia)

Third spacing (anasarca, hydrops, and vascular leakage)

Neonatal leukemia

Other conditions

Maternal immunosuppressive medication (azathioprine and 6-mercaptopurine and adalimumab)

Extreme preterm birth (T cells normalize over time)

Idiopathic T lymphopenia

* Table adapted from references [10, 12, 13]

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

Table 2 Definition of SCID variants based on Primary Immune Deficiency Treatment Consortium (PIDTC) criteria

Typical SCID	Leaky (Atypical) SCID	Omenn syndrome
Absence or very low number of T cells (CD3 T cells <300/uL) AND No or very low T cell function (< 10% of lower limit of normal) as measured by lymphocyte proliferative response to mitogen phytohemagglutinin (PHA) AND/OR T cells of maternal origin present	Reduced number of CD3 T cells <ul style="list-style-type: none"> • for age up to 2 years < 1000/uL • for > 2 years up to 4 years < 800/uL • for > 4 years < 600/uL Absence of maternal engraftment < 30% of lower limit of normal T cell function (as measured by lymphocyte proliferative response to mitogen PHA) Hypomorphic mutations in known SCID gene	Generalized skin rash Absence of maternal engraftment Detectable CD3 T cells, 300/mL Absent or low (up to 30% of normal) T cell proliferation to antigens to which the patient has been exposed If the proliferation to antigen was not performed, but at least 4 of the following supportive criteria, at least one of which must be among those marked with an asterisk (*) below, are present, the patient is eligible: <ul style="list-style-type: none"> • Hepatomegaly • Splenomegaly • Lymphadenopathy • Elevated IgE • Elevated absolute eosinophil count • *Oligoclonal T cells measured by CDR3 length or flow cytometry • * > 80% of CD3+ or CD4+ T cells are CD45RO+ • *Proliferation to PHA is reduced < 30% of lower limit of normal • *Proliferative response in mixed leukocyte reaction is reduced < 30% of lower limit of normal • *Mutation in SCID-causing gene

Adapted from references [14, 15]

Table 3

Genes linked to SCID and its variants and athymia presenting as SCID

		Immunophenotype			
		B+NK-	B+NK+	B-NK+	B-NK-
		<i>IL2RG</i>	<i>IL7R</i>	<i>RAG1</i>	<i>AK2</i>
		<i>JAK3</i>	<i>IL2RB</i>	<i>RAG2</i>	<i>ADA</i>
		<i>TBX1</i>	<i>PTPRC</i>	<i>DCLRE1C (Artemis)</i>	<i>PNP</i>
			<i>CD3D</i>	<i>PRKDC</i>	
			<i>CD3E</i>	<i>NHEJ1</i>	
Genes affected			<i>CD3Z</i>	<i>LIG4</i>	
			<i>CORO1A</i>		
			<i>LAT</i>		
			<i>NFKB1</i>		
			<i>ZAP70</i>		
			<i>del22q11</i>		

References [16–18]

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript